REPLIMUNE GROUP, INC.

Public Equity (NASDAQ)BiotechnologyOncologyPublic

📍 Woburn, MA, USA

StreetZero Signal 57

Be the first to signal interest

About REPLIMUNE GROUP, INC.

Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies to treat cancer. Its platform uses genetically engineered herpes simplex viruses designed to maximize tumor killing while inducing a systemic anti-tumor immune response. The company is headquartered in Woburn, Massachusetts and is publicly traded on NASDAQ under ticker REPL.

LATEST FUNDINGRule 144

$155K

Announced 2026-10-28

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for REPLIMUNE GROUP, INC..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

EMPLOYEES—

FOUNDED—

HQWoburn, MA, USA

Industry

Public Equity (NASDAQ)

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

NASDAQ-listed oncology company (REPL)
Focus on oncolytic virus platform
Rule 144 transaction of $154,744.8 with no disclosed investors

Ask StreetZero about REPLIMUNE GROUP, INC.

Put our AI to work on this deal.

What is REPLIMUNE GROUP, INC.'s value proposition?Who are REPLIMUNE GROUP, INC.'s competitors?Why does this raise matter?Summarize REPLIMUNE GROUP, INC. for an investor.

Similar companies

Other Public Equity (NASDAQ) deals, ranked by Signal.

Paylocity Holding Corporation

$66.0M

BENTLEY SYSTEMS INC

$67.5M

Crowdstrike Holdings, Inc.

$141.0M

Palo Alto Networks Inc

$201.4M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.